

1     **Molecular Epidemiology, Risk Factors and Clinical Outcomes of Carbapenem- and**  
2     **Polymyxin-Resistant Gram-negative Bacterial Infections in Pregnant Women and**  
3                     **Infants: A Systematic Review**

4                                     John Osei Sekyere<sup>1#</sup> and Melese Abate Reta<sup>1</sup>

5     <sup>1</sup>Department of Medical Microbiology, University of Pretoria, 0084 Prinshof Pretoria, South  
6     Africa

7     #Address correspondence to [jod14139@gmail.com](mailto:jod14139@gmail.com)

8     Tweet: “Clonal outbreaks of carbapenem- & colistin-resistant bacteria are common in neonatal intensive care  
9     units, causing very high mortalities. However, effective antibiotic therapy and infection control can prevent  
10    these deaths”

11    **Highlights**

- 12         • Carbapenems & polymyxins are last-resort antibiotics used for multidrug-resistant  
13         infections
- 14         • Resistance to these two agents are reported in infants & pregnant women
- 15         • *K. pneumoniae*, *E. coli*, and *A. baumannii* are the most common pathogens
- 16         • Carbapenem & polymyxin resistance cause outbreaks with high infant mortalities
- 17         • Appropriate treatment & infection control can outbreaks & save lives

18

19

20

21

22

23 **Abstract**

24 **Background.** Carbapenems and polymyxins are last-resort antibiotics used to treat  
25 multidrug-resistant bacterial infections. However, resistance is increasing, even in vulnerable  
26 groups such as pregnant women and infants, for whom therapeutic options are limited.

27 **Method.** Using a diversity of databases, the literature was searched for studies investigating  
28 carbapenem and polymyxin resistance in pregnant women and infants (< 5 years).

29 **Result.** A final set of 73 manuscripts were used. In almost all countries,  
30 carbapenem/polymyxin-resistant *Klebsiella pneumoniae*, *Escherichia coli*, and *Acinetobacter*  
31 *baumannii* infect and/or colonizes neonates and pregnant women, causing periodic outbreaks  
32 with very high infant mortalities. Plasmid-borne *bla*<sub>NDM</sub>, *bla*<sub>KPC</sub>, *bla*<sub>OXA-48</sub>, *bla*<sub>IMP</sub>, *bla*<sub>VIM</sub> and  
33 *bla*<sub>GES-5</sub> and ompK35/36 downregulation in clonal strains accelerate the horizontal and  
34 vertical transmission of carbapenem resistance in these pathogens. High prevalence of  
35 carbapenem/polymyxin resistance and carbapenemases were present in India, China,  
36 Pakistan, Thailand, Taiwan, Turkey, Egypt, Italy, USA, South Africa, Algeria, Ghana, and  
37 Madagascar. Factors such as antibiotic therapy, prolonged hospitalization, invasive  
38 procedures, mother/infant colonization, mechanical ventilation, low-birth weight and preterm  
39 state placed infants at high risk of carbapenem/polymyxin-resistant infections. Infant  
40 mortalities ranged from 0.2% to 36.8% in different countries.

41 **Conclusion.** Use of polymyxins to treat carbapenem-resistant infections is selecting for  
42 resistance to both agents, restricting therapeutic options for infected infants and pregnant  
43 women. However, appropriate infection control and antibiotic therapy can contain outbreaks  
44 and clear these infections. Antibiotic stewardship, periodic rectal and vaginal screening, and  
45 strict infection control practices in neonatal ICUs are necessary to forestall future outbreaks  
46 and deaths.

47 **Keywords:** Carbapenem; polymyxin; colistin; carbapenemase; antibiotic resistance; pregnant  
48 women; infants; neonates.

## 49 **Introduction**

50 Resistance to antimicrobials remain a major challenge to public health, veterinary medicine,  
51 agriculture and aquaculture globally, owing to the limited or no therapeutic option available  
52 to treat multidrug-resistant (MDR) infections<sup>1-5</sup>. To avoid depleting our antibiotics arsenals  
53 against infectious pathogens, certain agents are reserved as last-line drugs to fight difficult-to-  
54 treat infections<sup>6-8</sup>. Currently, carbapenems, polymyxins (colistin) and tigecycline are used as  
55 reserved agents for MDR infections<sup>9,10</sup>. However, the continual use of carbapenems and  
56 polymyxins to treat bacterial infections resistant to penicillins, cephalosporins, and  
57 carbapenems are increasing the rate of resistance to these last-resort antibiotics<sup>2,4,9,11</sup>. The  
58 emergence of carbapenem- and/or polymyxin-resistant MDR infections is thus limiting  
59 therapeutic options and increasing hospital stay, healthcare costs, morbidity, and mortality<sup>12-</sup>  
60 <sup>14</sup>. Subsequently, the WHO has classified carbapenem-resistant Gram-negative bacteria (CR-  
61 GNB) as critical priority pathogens for which novel antibiotics are urgently needed<sup>15,16</sup>.

62 Pregnant women and infants (below 5 years old) are a vulnerable population with regards to  
63 bacterial infections due to their unbalanced and less matured immune system, respectively,  
64 and the limited therapeutic options available to them<sup>17-19</sup>. Hence, the presence of MDR  
65 carbapenem and/or polymyxin-resistant infections among pregnant women and infants make  
66 them more susceptible to the ramifications of the infection<sup>13,19,20</sup>. Whereas several studies  
67 have reported on pregnant women colonized with CR-GNB than infected by it, there is a risk  
68 of colonized pregnant women transferring these CR-GNB to their new borns<sup>19,21-24</sup>. It is  
69 therefore not surprising that numerous studies report on CR-GNB- and polymyxin-resistant  
70 Gram-negative bacteria (PR-GNB)-infected neonates than colonized ones<sup>20,23,25,26</sup>. Further,

71 there have been abundant reports of clonal and polyclonal CR-GNB outbreaks in neonatal  
72 intensive care units (NICUs) globally, claiming the lives of several neonates as a result<sup>18,27-</sup>  
73 <sup>29</sup>. This makes neonates more susceptible to CR-GNB and PR-GNB infections with their  
74 associated morbidity and mortality<sup>17-20,30</sup>.

75 Notably, CR-GNB and PR-GNB carry other antibiotic resistance genes (ARGs) on mobile  
76 plasmids, transposons, integrons, integrative conjugative elements (ICE), and insertion  
77 sequences (ISs) that facilitate the horizontal transmission of these ARGs between species and  
78 clones<sup>13,20,31-33</sup>. Specifically, extended-spectrum  $\beta$ -lactamases (ESBLs), fluoroquinolones,  
79 aminoglycosides, tetracycline, sulphamethoxazole-trimethoprim, and macrolide ARGs are  
80 also found in CR-GNB and PR-GNB. Hence, under antibiotic selection pressure, MDR  
81 plasmids and clones proliferate, leading to outbreaks<sup>10,27,34,35</sup>. It is thus not surprising that  
82 most neonatal CRE infections occur in NICUs during clonal outbreaks in which the isolates  
83 harbour multiple ARGs on mobile plasmids<sup>20,25,26,30,36,37</sup>. Analyses of the data obtained from  
84 this study confirms this observation.

### 85 *Evidence before this review*

86 A thorough review of the literature showed the absence of a review addressing carbapenem  
87 and polymyxin resistance among pregnant women and neonates. Only one review addressed  
88 carbapenem-resistance among Gram-negative bacteria (GNB) in children<sup>14</sup> whilst another  
89 only addressed CRE-causing neonatal sepsis in China<sup>38</sup>. Thus, this is the first work to  
90 systematically review and statistically analyse the literature on carbapenem and polymyxin  
91 resistance among pregnant women and infants.

### 92 *Literature & databases search strategy*

93 All literature published in English were searched on Medline/PubMed, Web of Science,  
94 ScienceDirect, HINARI, Cochrane library electronic databases, and Google scholar using the

95 following search words: "Gram-negative bacteria", "epidemiology", "prevalence",  
96 "incidence", "risk factors", "determinant", "associated factors", "carbapenem", "carbapenem  
97 resistance", "colistin", "polymyxin resistance", "carbapenem-resistant Gram-negative  
98 bacteria", "colistin-resistant Gram-negative bacteria", "carbapenem resistance determinants",  
99 "carbapenem resistance genotypes", "carbapenem resistance mechanisms", "colistin  
100 resistance determinants", "colistin resistance genotypes", "colistin resistance mechanisms",  
101 "infants", "neonates", "children" and "pregnant women". These search words were further  
102 paired with each other in a factorial fashion and search strings were implemented using  
103 "AND" and "OR" Boolean operators. "OR" was used between "colistin" and "polymyxin" as  
104 in "colistin OR polymyxin". No other filters were employed and the search was carried out  
105 up to 30<sup>th</sup> September 2020. Both authors undertook the literature search, title and abstract  
106 screening and resolved outstanding discrepancies by consensus, using the inclusion and  
107 exclusion criteria.

#### 108 ***Inclusion and exclusion criteria***

109 All articles addressing the following were included: 1) molecular testing of carbapenem- and  
110 polymyxin (colistin)-resistant GNB isolated from pregnant women and/or infants; 2)  
111 phenotypic antimicrobial sensitivity testing (AST) of carbapenem and polymyxin (colistin)-  
112 resistant GNB isolated from pregnant women and/or infants; 3) epidemiology (incidence,  
113 prevalence, risk factors and/or clinical outcomes) of carbapenem and/or polymyxin (colistin)  
114 resistance in pregnant women and/or infants (<5years old); 4) articles on pregnant women  
115 and infants with carbapenem or polymyxin (colistin)-resistant infections or colonization.  
116 Articles reporting on carbapenem-and/or polymyxin (colistin)-resistant GNB isolated from  
117 non-pregnant women and/or infants greater than 5 years old were excluded.

118 ***Statistical analyses***

119 Data on isolation country, year of isolation, carbapenem and polymyxin resistance profiles,  
120 GNB species and clones, carbapenem and polymyxin resistance mechanisms, age, sex,  
121 clinical history, colonization or infection, clinical history, previous and current medications,  
122 clinical outcomes, mortality rate and risk factors were extracted from the included articles  
123 and populated into Microsoft Excel. Further analyses were undertaken to compute isolation  
124 rates, prevalence, resistance rates, and mortality rates per country (Tables S1-S3).

125 **Results**

126 ***Included studies and samples***

127 A total of 1427 articles were retrieved from the various databases, of which 73 studies from  
128 28 countries worldwide were finally included for the qualitative and quantitative analyses  
129 (Figure S1). Studies describing carbapenem resistance in infants (n = 65 studies) were from  
130 24 countries, involved 49 154 infants (< 5 years), and resulted in the isolation of 11 441 GNB  
131 cultures with 23.3% isolation rate (Table S1). Carbapenem resistance in pregnant women (n =  
132 7 studies) were reported from six countries among 1892 pregnant women; this resulted in 285  
133 GNB cultures and an isolation rate of 15.1% (Table S2). Included studies on polymyxin  
134 resistance (n = 7) were mainly in infants (n = 16 556), with one being from a pregnant  
135 woman<sup>39</sup>; 1345 GNB cultures were obtained, yielding an isolation rate of 8.1% (Table S3)  
136 (Figure S2).

137 Fifty studies on infants involved carbapenem resistance infections, 11 involved colonization  
138 by CR-GNB, and four involved both infection and colonization. At least 22 studies out of the  
139 50 describing GNB infections in neonates involved sepsis cases (Table S1). Notably, all the  
140 studies on PR-GNB in infants also involved infection cases with no colonizations (Table S3).  
141 However, six of the seven studies on CR-GNB in pregnant women were mainly colonization

142 cases with no infections, with only one study being an infection case in the USA (Table S2).

143 There were higher GNB isolations from India, Bangladesh, Pakistan, Morocco, China,

144 Turkey, South Africa, USA, and Cambodia than from the other countries (Figure S2).

#### 145 *Species, clones, and resistance rates*

146 On a per country basis, *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*,

147 *Enterobacter sp.* (cloacae), and *Pseudomonas aeruginosa* were the most dominant species

148 causing infections or colonization in infants and pregnant women, with *Citrobacter sp.*,

149 *Proteus sp.*, *Morganella sp.*, *Serratia sp.*, and *Salmonella sp.* being some of the less common

150 species (Figure 1). Although these species differed in terms of prevalence per country, *E.*

151 *coli*, *K. pneumoniae* and *A. baumannii* were the most common in almost all countries whilst

152 *Pseudomonas aeruginosa* were highly prevalent in Italy, Nepal, USA, Turkey, and Kenya.

153 The dominant clones of the various species were mainly localized within countries with few

154 clones being observed across countries. For instance, only *K. pneumoniae* ST11 (in India,

155 China, and multiple settings), *K. pneumoniae* ST15 (India, China, and Nepal), *K. pneumoniae*

156 ST17 (Ghana and China) were observed across countries. Relatively few studies

157 characterized the CR-GNB isolates to determine their clonality whilst others used PFGE or

158 REP-PCR, limiting an effective international clonal analyses (Figure 2). Yet, the various

159 clones identified within the countries were mostly involved in outbreaks in neonatal intensive

160 care units (NICU) <sup>40-45</sup>.

161 Carbapenem resistance among infants in the various countries were substantial, particularly

162 in India, Pakistan, China, Egypt, Taiwan, Thailand, and USA whilst polymyxin resistance

163 rate in infants was high in Thailand, India, Malaysia, and Nepal. In pregnant women, Algeria,

164 Madagascar, and Mexico recorded the highest number of CR-GNB colonizations (Figure 3).

### 165 ***Carbapenem & polymyxin resistance determinants***

166 Carbapenem resistance among CR-GNB in both infants and pregnant women were mainly  
167 mediated by carbapenemases in all countries, with few reports of non-carbapenemases such  
168 as ompK35 and ompK36 porins loss (Italy), penicillin-binding protein mutations (PBP3)  
169 (Malaysia), OXA-1  $\beta$ -lactamase (China), and soxS and marA efflux regulators (Malaysia),  
170 mediating carbapenem resistance. GES-5 (Poland), IMP (Japan and China), and VIM (Italy,  
171 Hungary, and Morocco) carbapenemases were mainly dominant in single or few countries or  
172 regions (such as the Mediterranean region) whilst NDM, KPC, and OXA-48-like variants  
173 were common in many countries among infants and pregnant women. Polymyxin resistance  
174 mechanisms were largely not described in the included studies, except in one study by Naha  
175 et al. (2020) in which overexpression of acrB, tolC, ramA, and soxS were found to mediate  
176 colistin resistance<sup>36</sup> and in another study by Zeng et al. (2016) in which *mcr-I* was found in  
177 an *Enterobacter* (now *Klebsiella*) *aerogenes* isolate (Figure 3).

### 178 ***Risk factors and mortality rates***

179 Risk factors associated with CR-GNB and PR-GNB infections and colonization differed  
180 slightly between countries, with factors such as previous and/or long hospitalization, previous  
181 and/or ongoing antibiotic therapy, invasive procedures such as caesarian section, intubation,  
182 and catheterization, preterm and low birth weight infants, and mechanical ventilation being  
183 common risk factors in almost all countries. Whereas PR-GNB-associated mortalities were  
184 not reported, CR-GNB-associated mortalities were above 10% in Brazil, China, Egypt,  
185 Hungary, and Thailand and noticeably lower than 10% in India, Nepal, Turkey, Pakistan,  
186 Italy, and Cambodia.

### 187 **Discussion**

188 Carbapenem- and/or polymyxin-resistant GNB are common in neonates and pregnant women  
189 in several countries as either infections or colonizations, threatening the lives of the affected  
190 patients as CR-GNB and PR-GNB are associated with longer hospitalization and higher  
191 morbidities and mortalities<sup>29,46–48</sup>. Worryingly, many of the studies involved in this review  
192 reported on clonal and polyclonal outbreaks and infections of CR-GNB or PR-GNB among  
193 neonates in NICUs or colonization of CR-GNB in pregnant women involving pathogenic  
194 GNB such as *A. baumannii*, *E. coli*, *Enterobacter sp.*, *K. pneumoniae*, and *P. aeruginosa*  
195 (Tables S1-S3). In most of these CR-GNB, carbapenemases, including NDM, OXA-48,  
196 KPC, VIM, IMP, and GES-5 were found on mobile plasmids within transposons, insertion  
197 sequences, and integrons.

198 Notably, carbapenem-resistant *A. baumannii*, *E. coli*, and *K. pneumoniae* harbouring mobile  
199 plasmid-borne carbapenemases cause outbreaks in neonates with sepsis, pneumonia, and  
200 other infections in NICUs in several countries worldwide, resulting in very high mortalities  
201 (Table S1)<sup>17,43,49–51</sup>. For instance, carbapenem-resistant *A. baumannii* outbreaks were  
202 reported by Lee et al. (2018), Sultan and Seliem (2018), Indhar et al. (2017), Al-lawama et al.  
203 (2016), Thatrimontrichai et al. (2015), Kumar et al. (2014), and Tekin et al. (2013) in Taiwan,  
204 Egypt, Pakistan, Jordan, Greece, India, and Turkey respectively, killing several infants<sup>19,51–</sup>  
205 <sup>56</sup>. *E. coli* neonatal infections and outbreaks were reported in Japan with an IMP-11  
206 carbapenemase<sup>37</sup>, in China with nine NDM-5-producing ST410 strains<sup>45</sup> and NDM-5-  
207 positive ST167<sup>33</sup>, in Turkey with an OXA-48-producing strain<sup>43</sup>, and in India with NDM-1-  
208 positive clonal strains from the body of infants and the ward environment<sup>42</sup>. Comparatively,  
209 outbreaks in NICUs involving *K. pneumoniae* were globally reported, involving NICUs  
210 infections, colonizations, mobile plasmid-borne *bla*<sub>NDM</sub>, *bla*<sub>KPC</sub>, *bla*<sub>OXA-48</sub>, *bla*<sub>IMP</sub>, *bla*<sub>VIM</sub> and  
211 *bla*<sub>GES-5</sub> carbapenemases, and very high mortalities, making *K. pneumoniae* the most deadly  
212 and common neonatal MDR pathogen<sup>13,18,25,27,28,31,36,40,41,43,44,49,50,57–63</sup>.

213 Similarly, PR-GNB infections were also common in the same species viz., *A. baumannii*, *E.*  
214 *coli*, *K. pneumoniae*, *Enterobacter sp.* and *Pseudomonas sp.*, although reports on outbreaks  
215 were either associated with carbapenem resistance<sup>34,36</sup> or absent. Hence, outbreaks involving  
216 CR-GNB that were also polymyxin resistant could also be referred to as PR-GNB outbreaks,  
217 which makes such infections very difficult to manage<sup>1,2,4,9</sup>. The largest collection of PR-  
218 GNB was recorded in Malaysia from preterm infants in a NICU in 2016, eight of which were  
219 carbapenem-resistant *K. pneumoniae*<sup>34</sup>. A colistin-resistant *C. freundii* isolate was  
220 subsequently isolated from the stool of a preterm infant in the same hospital in Malaysia,  
221 suggesting the persistence of PR-GNB in that setting<sup>64</sup>. Naha et al. (2020) observed that  
222 overexpression of *acrB*, *tolC*, *ramA*, and *soxS* conferred colistin resistance in a carbapenem-  
223 resistant *K. pneumoniae* ST147, which could have been the resistance mechanism in the *C.*  
224 *freundii* isolate from Malaysia<sup>36,64</sup>. Although *mcr* genes, and not chromosomal mutations, are  
225 the most common mechanisms mediating polymyxin resistance globally<sup>1,2,4,9</sup>, an *mcr-1* was  
226 only identified in one study (in *E. aerogenes*, now *K. aerogenes*) and interestingly, from the  
227 vaginal secretions of a pregnant woman<sup>39</sup>.

228 Hence, vaginal swabbing could also be used to screen for CR/PR-GNB in pregnant women  
229 besides rectal swabbing as such important pathogens can be missed if they do not occur in the  
230 gut. Further, the presence of CR/PR-GNB in the vagina could explain the colonization of  
231 infants and wards with these MDR pathogens as they can pick up these bacteria during birth  
232<sup>39,42</sup>. If gut colonization of pregnant women with CR-GNB could potentially lead to  
233 colonization and/or infection of the neonate<sup>22,24,65</sup>, then vaginal colonization could even lead  
234 to a more direct effect than gut colonization, making vaginal screening of pregnant women an  
235 important means of preventing CR/PR-GNB infections and mortalities in neonates. The  
236 means by which infants become colonized by CR/PR-GNB remains enigmatic, although  
237 direct inoculation from mothers is highly likely. Nevertheless, neonatal colonization with

238 CR/PR-GNB is not only obtained from the mother as observed by other clinicians  
239 <sup>20,23,26,42,61,66,67</sup> .

240 In particular, neonates can become colonized and later infected with CR/PR-GNB during  
241 antibiotic therapy <sup>23,68</sup> , long-stay in wards (NICU) with endemic CR/PR-GNB <sup>42,67</sup> , handling  
242 by healthcare workers, breastfeeding by colonized mothers, intubation, during labour or  
243 caesarian section <sup>24,65,66</sup> , mechanized ventilation, from the community <sup>23,61</sup> etc. (Tables S1-  
244 S3). To establish a direct relationship between mother and infant colonization, and with  
245 infant colonization and infection, then a clonal analyses of isolates would have to be  
246 undertaken. As yet, studies showing this clonal relationship between GNB isolates from  
247 mother and neonate, and between neonate colonization and infection, are wanting (Figure 2).  
248 Despite the larger number of studies reporting on pregnant women colonization, there are  
249 relatively few reports of pregnant women infection with CR/-PR-GNB, suggesting that  
250 colonization does not necessarily lead to infections in pregnant women or that their stronger  
251 and much developed immune system makes them less susceptible to CR/PR-GNB infections.  
252 Hence, CR/PR-GNB colonization in pregnant women is more of a risk to neonates than to the  
253 women themselves. Nevertheless, infection of pregnant women with CR/PR-GNB could  
254 complicate their pregnancies and put their lives at risk <sup>46</sup> .

255 The clonality of the species infecting both pregnant women and infants were not the same,  
256 suggesting little dissemination between colonized mothers and neonates. Further, there were  
257 very few clones of *K. pneumoniae* that were seen in at most three countries, with almost all  
258 the reported clones of all the species being local and restricted to single hospitals and wards  
259 (Figure 2; Tables S1-S3). This demonstrates limited circulation of the same clone even within  
260 a community, ward, hospital or country.

261 The carbapenemases found in the CR-GNB isolates mirrored those found in the same  
262 countries and regions (Figure 4). For instance, IMP and VIM are common in Japan/China and  
263 Italy (Europe) respectively, OXA-48 is common in the mediterranean region, Middle-East  
264 and South Africa whilst KPC and NDM are globally distributed <sup>69</sup>. This global epidemiology  
265 of carbapenemases is reflected in the epidemiology of carbapenemases in the infants and  
266 pregnant women (Figure 4), further corroborating the localized transmission of CR-GNB in  
267 neonates. In addition, the higher prevalence of NDM, KPC, and OXA-48-like  
268 carbapenemases over VIM and IMP <sup>69</sup>, also reflects the global prevalence of these  $\beta$ -  
269 lactamases in neonates (Figure 4). The carbapenemases were mainly found on mobile  
270 plasmids (IncFII, IncX<sub>3</sub>, IncN), integrons (*IntI1*), insertion sequences (*ISKpn7*, *ISKpn6*,  
271 *ISAbal25*, *IS26*) and transposons (*Tn4401b*), which facilitates their movement from  
272 chromosomes to plasmids, plasmids to plasmids, and between cells of the same or different  
273 species <sup>13,20,26,31,32,36,37,42,45,60,70</sup> .

274 Specifically, NDM-5 carbapenemases were found on IncX<sub>3</sub> and IncFII plasmids in *K.*  
275 *quasipneumoniae* ST476 (in Nigeria) and *E. coli* ST410 (in China) respectively, which were  
276 causing outbreaks in NICUs. The immediate genetic environment of the NDM-5 on these  
277 plasmids were exactly the same or similar, suggesting that same plasmids and/or clones were  
278 mediating the spread of NDM-5 within and between species <sup>31,45</sup>. The higher mobility of  
279 these carbapenemases may explain their faster dissemination between neonates in wards and  
280 hospitals during outbreaks and evinces the need to undertake molecular analyses of isolates to  
281 comprehend their epidemiology <sup>1,2,4,9,69</sup> .

282 Not all CR-GNB isolates contained carbapenemases. Isolates without carbapenemases, but  
283 with ESBLs such as CTX-M, TEM, SHV, and OXA, coupled with the loss or downregulation  
284 of porins ompK35 and ompK36, had very high resistance to carbapenems <sup>27,44,59</sup>. In Italy,  
285 such strains resulted in mortalities as high as 28.5% <sup>59</sup> .

286 Prevalence of CR/PR-GNB and carbapenemases were higher in countries with higher GNB  
287 isolation rates (Figure 3-4), which is expected as most clinical investigations are undertaken  
288 in response to increasing infections or outbreaks. Further, susceptible GNB are hardly  
289 published except when they are isolated together with resistant GNB, making the literature  
290 skewed towards resistant GNB cases. Higher reports of carbapenemases were observed in  
291 China, India, Ghana, Italy, Hungary, Turkey, South Africa, Algeria and Madagascar (in  
292 pregnant women), which does not fully reflect the carbapenem resistance rates shown in  
293 Figure 3 as not all studies investigated the underlying carbapenem resistance mechanism. For  
294 instance, Cambodia, Egypt, Greece, Pakistan, Taiwan, Thailand, and USA had higher  
295 resistance rates, but very few or no report of carbapenemases. Whereas this may be due to  
296 financial limitations in low- and middle-income countries (LMICs), the same can not be true  
297 of wealthier countries such as Taiwan, Thailand, and the USA. Hence, there is the need for  
298 increasing awareness among clinicians and researchers on the need to undertake advanced  
299 genomics analyses of resistant GNB to facilitate epidemiological analyses and interventions.

300 On the other hand, countries with higher prevalence of carbapenemases and carbapenem  
301 resistance rates should immediately institute effective infection control and prevention  
302 practices as sufficient evidence indicates that this can both prevent and contain CR/PR-GNB  
303 outbreaks<sup>41,63</sup>. Particularly, the nosocomial colonization of neonates with clonally related  
304 carbapenemase-producing *P. aeruginosa* in a NICU and the subsequent isolation of a VIM-  
305 14 carbapenemase in the same pathogen in a NICU, both in Italy<sup>71,72</sup>, depict the endemic  
306 presence of this carbapenemase-producing pathogen within those periods in the affected  
307 regions. This signals the urgency required in instituting effective interventions to clear these  
308 MDR pathogens and save further lives as outbreaks in NICUs are associated with very high  
309 mortalities<sup>29,50,54</sup>.

310 Common risk factors for getting CR/PR-GNB infections across all countries have been stated  
311 above: they include include colonization of the infant or mother with CR/PR-GNB, long-term  
312 hospitalization in NICUs, undergoing invasive procedures and previous, ongoing or longer  
313 antibiotic therapy, mechanical ventilation, preterm state, and low birth weight (Fig. 5)<sup>22,55,57</sup>.  
314 Interestingly, neonatal colonization with CR/PR-GNB during NICU stay can later result in  
315 community and nosocomial infections as described by Vergadi et al. (2017)<sup>61</sup>. Sadly, infant  
316 mortalities from CR/PR-GNB remains substantially high in many countries, including China  
317 and Brazil (Fig. 6), albeit treatment with carbapenems (at higher doses), colistin, and  
318 tigecycline have been shown to be very efficient in clearing the infection and saving lives  
319 <sup>7,10,28,45,56,73</sup>. Instructively, Kumar et al. (2014) observed that the absence of effective  
320 treatment led to higher all-cause mortalities in neonates<sup>54</sup>.

### 321 ***Conclusion and future perspectives***

322 Evidently, carbapenem and polymyxin resistance is common in GNB isolated from infants  
323 and pregnant women, with high resistance rates and diverse carbapenemases globally,  
324 particularly in India, China, Pakistan, Thailand, Algeria, South Africa, Turkey, Ghana,  
325 Hungary, and Italy. In almost all these countries, there were local clonal outbreaks involving  
326 *A. baumannii*, *E. coli*, *Enterobacter sp.*, *K. pneumoniae*, and *P. aeruginosa* clones hosting  
327 mobile plasmids, integrons, insertion sequences, and transposons on which were found  
328 *bla*<sub>NDM</sub>, *bla*<sub>KPC</sub>, *bla*<sub>OXA-48</sub>, *bla*<sub>IMP</sub>, *bla*<sub>VIM</sub> and *bla*<sub>GES-5</sub> carbapenemases. Whereas colonization  
329 in pregnant women is a risk factor for neonatal infections and outbreaks, infections in  
330 pregnant women can complicate their pregnancies. Infection with CR/PR-GNB has been  
331 associated with very high mortality rates among infants, necessitating urgent infection control  
332 interventions to prevent further outbreaks and safeguard lives. The commonality of risk  
333 factors for getting CR/PR-GNB infections in all countries indicate that adopting a standard  
334 and strict infection control measures in all healthcare centres globally can contain these

335 pathogens from causing further infections. Several outbreaks have been contained with strict  
336 infection control interventions.

337 Fortunately, treatment of CR/PR-GNB infections is possible with polymyxins, higher doses  
338 of carbapenems, tigecycline, amikacin, and avibactam/sulbactam-cephalosporin/carbapenem  
339 combinations. Such treatment protocols and medicines must be distributed to all  
340 paediatricians and enforced to reduce infant mortalities. Nevertheless caution with antibiotic  
341 therapy (stewardship) must be also advised as it is a risk factor for acquired carbapenem  
342 resistance colonization or infection.

343 Going forward, periodic genomic (molecular) surveillance/screening of hospitals (wards) and  
344 patients must be instituted to pre-emptively identify patients with CR/PR-GNB infections or  
345 colonization. Particularly, vaginal and rectal screening of pregnant women can help in  
346 surveillance exercises. Further genomic analyses to identify the clones, plasmids, and  
347 resistance mechanisms shall inform the appropriate intervention to adopt to break the chain of  
348 transmission.

349 **Acknowledgments:** None

350 **Funding:** None

351 **Transparency declaration:** None

## 352 **References**

- 353 1. Osei Sekyere, J. & Reta, M. A. Genomic and Resistance Epidemiology of Gram-Negative Bacteria in  
354 Africa: a Systematic Review and Phylogenomic Analyses from a One Health Perspective. *mSystems* **5**,  
355 (2020).
- 356 2. Kopotsa, K., Mbelle, N. M. & Osei Sekyere, J. Epigenomics, Genomics, Resistome, Mobilome,  
357 Virulome and Evolutionary Phylogenomics of Carbapenem-resistant *Klebsiella pneumoniae* clinical  
358 strains. *Microb. genomics genomics* (2020). doi:10.1101/2020.06.20.20135632
- 359 3. Osei Sekyere, J. & Mensah, E. Molecular epidemiology and mechanisms of antibiotic resistance in

- 360 Enterococcus spp., Staphylococcus spp., and Streptococcus spp. in Africa: a systematic review from a  
361 One Health perspective. *Ann. N. Y. Acad. Sci.* **1465**, 29–58 (2020).
- 362 4. Osei Sekyere, J., Maningi, N. E., Modipane, L. & Mbelle, N. M. Emergence of mcr-9.1 in ESBL-  
363 producing Clinical Enterobacteriaceae in Pretoria, South Africa: Global Evolutionary Phylogenomics,  
364 Resistome and Mobilome. *mSystems* **5**, e00148-20 (2020).
- 365 5. Van Boeckel, T. P. *et al.* Global trends in antimicrobial resistance in animals in low- and middle-income  
366 countries. *Science (80-. )*. **365**, eaaw1944 (2019).
- 367 6. Osei Sekyere, J., Govinden, U., Bester, L. A. & Essack, S. Y. Colistin and Tigecycline Resistance In  
368 Carbapenemase-Producing Gram Negative Bacteria: Emerging Resistance Mechanisms And Detection  
369 Methods. *J. Appl. Microbiol.* **121**, 601–617 (2016).
- 370 7. Cagan, E., Kiray Bas, E. & Asker, H. S. Use of Colistin in a Neonatal Intensive Care Unit: A Cohort  
371 Study of 65 Patients. *Med. Sci. Monit.* **23**, 548–554 (2017).
- 372 8. Osei Sekyere, J. Current State of Resistance to Antibiotics of Last-Resort in South Africa: A Review  
373 from a Public Health Perspective. *Front. Public Heal.* **4**, 209 (2016).
- 374 9. Mmatli, M., Mbelle, N. M., Maningi, N. E. & Osei Sekyere, J. Emerging Transcriptional and Genomic  
375 Mechanisms Mediating Carbapenem and Polymyxin Resistance in Enterobacteriaceae: a Systematic  
376 Review of Current Reports. *mSystems* **5**, (2020).
- 377 10. Almohammady, M. N., Eltahlawy, E. M. & Reda, N. M. Pattern of bacterial profile and antibiotic  
378 susceptibility among neonatal sepsis cases at Cairo University Children Hospital. *J. Taibah Univ. Med.*  
379 *Sci.* **15**, 39–47 (2020).
- 380 11. Karaaslan, A. *et al.* Intravenous Colistin Use for Multidrug-Resistant Gram-Negative Infections in  
381 Pediatric Patients. *Balkan Med. J.* **33**, 627–632 (2016).
- 382 12. Mularoni, A. *et al.* Epidemiology and successful containment of a carbapenem-resistant  
383 Enterobacteriaceae outbreak in a Southern Italian Transplant Institute. *Transpl. Infect. Dis.* **21**, e13119  
384 (2019).
- 385 13. Ahmad, N., Ali, S. M. & Khan, A. U. Molecular characterization of novel sequence type of  
386 carbapenem-resistant New Delhi metallo-beta-lactamase-1-producing *Klebsiella pneumoniae* in the  
387 neonatal intensive care unit of an Indian hospital. *Int. J. Antimicrob. Agents* **53**, 525–529 (2019).
- 388 14. Aguilera-Alonso, D., Escosa-García, L., Saavedra-Lozano, J., Cercenado, E. & Baquero-Artigao, F.  
389 Carbapenem-resistant Gram-negative bacterial infections in children. *Antimicrobial Agents and*  
390 *Chemotherapy* **64**, (2020).
- 391 15. Tacconelli, E. *et al.* Discovery, research, and development of new antibiotics: the WHO priority list of  
392 antibiotic-resistant bacteria and tuberculosis. *Lancet. Infect. Dis.* **18**, 318–327 (2018).
- 393 16. Asokan, G. V, Ramadhan, T., Ahmed, E. & Sanad, H. WHO Global Priority Pathogens List: A

- 394 Bibliometric Analysis of Medline-PubMed for Knowledge Mobilization to Infection Prevention and  
395 Control Practices in Bahrain. *Oman Med. J.* **34**, 184–193 (2019).
- 396 17. Jajoo, M. *et al.* Alarming rates of antimicrobial resistance and fungal sepsis in outborn neonates in  
397 North India. *PLoS One* **13**, e0180705 (2018).
- 398 18. Essel, V. *et al.* A multisectoral investigation of a neonatal unit outbreak of *Klebsiella pneumoniae*  
399 bacteraemia at a regional hospital in Gauteng Province, South Africa. *South African Med. J.* **110**, 783–  
400 790 (2020).
- 401 19. Thatrimontrichai, A. *et al.* Risk factors and outcomes of carbapenem-resistant *Acinetobacter baumannii*  
402 ventilator-associated pneumonia in the neonate: A case-case-control study. *J. Infect. Chemother.* **22**,  
403 444–449 (2016).
- 404 20. Ahmad, N., Khalid, S., Ali, S. M. & Khan, A. U. Occurrence of blaNDM Variants Among  
405 Enterobacteriaceae From a Neonatal Intensive Care Unit in a Northern India Hospital. *Front.*  
406 *Microbiol.* **9**, 407 (2018).
- 407 21. Chabah, M. *et al.* Healthcare-associated infections due to carbapenemase-producing Enterobacteriaceae:  
408 Bacteriological profile and risk factors. *Med. Mal. Infect.* **46**, 157–162 (2016).
- 409 22. Chereau, F. *et al.* Colonization of extended-spectrum- $\beta$ -lactamase- and NDM-1-producing  
410 Enterobacteriaceae among pregnant women in the community in a low-income country: A potential  
411 reservoir for transmission of multiresistant Enterobacteriaceae to neonates. *Antimicrob. Agents*  
412 *Chemother.* **59**, 3652–3655 (2015).
- 413 23. Clock, S. A. *et al.* Colonization With Antimicrobial-Resistant Gram-Negative Bacilli at Neonatal  
414 Intensive Care Unit Discharge. **6**, 219–226 (2017).
- 415 24. Mairi, A. *et al.* Carbapenemase-producing Enterobacteriaceae among pregnant women and newborns in  
416 Algeria: Prevalence, molecular characterization, maternal-neonatal transmission, and risk factors for  
417 carriage. *Am. J. Infect. Control* **47**, 105–108 (2019).
- 418 25. Literacka, E. *et al.* Spread of *Klebsiella pneumoniae* ST45 Producing GES-5 Carbapenemase or GES-1  
419 Extended-Spectrum  $\beta$ -Lactamase in Newborns and Infants. *Antimicrobial agents and chemotherapy* **64**,  
420 6–9 (2020).
- 421 26. Arhoune, B. *et al.* Rectal carriage of extended-spectrum beta-lactamase- and carbapenemase-producing  
422 Enterobacteriaceae among hospitalised neonates in a neonatal intensive care unit in Fez, Morocco. *J.*  
423 *Glob. Antimicrob. Resist.* **8**, 90–96 (2017).
- 424 27. Datta, S. *et al.* A five-year experience of carbapenem resistance in Enterobacteriaceae causing neonatal  
425 septicaemia: predominance of NDM-1. *PLoS One* **9**, e112101 (2014).
- 426 28. Huang, X. *et al.* Characteristics of NDM-1-producing *Klebsiella pneumoniae* ST234 and ST1412  
427 isolates spread in a neonatal unit. *BMC Microbiol.* **18**, 186 (2018).

- 428 29. Johnson, J. *et al.* High Burden of Bloodstream Infections Associated With Antimicrobial Resistance and  
429 Mortality in the Neonatal Intensive Care Unit in Pune, India. *Clin. Infect. Dis.* (2020).  
430 doi:10.1093/cid/ciaa554
- 431 30. Liu, J. *et al.* Emergence and establishment of KPC-2-producing ST11 Klebsiella pneumoniae in a  
432 general hospital in Shanghai, China. *Eur. J. Clin. Microbiol. Infect. Dis.* **37**, 293–299 (2018).
- 433 31. Brinkac, L. M. *et al.* Emergence of New Delhi Metallo-beta-Lactamase (NDM-5) in Klebsiella  
434 quasipneumoniae from Neonates in a Nigerian Hospital. *mSphere* **4**, (2019).
- 435 32. Islam, M. A. *et al.* Occurrence and characterization of multidrug-resistant New Delhi metallo-beta-  
436 lactamase-1-producing bacteria isolated between 2003 and 2010 in Bangladesh. *J. Med. Microbiol.* **62**,  
437 62–68 (2013).
- 438 33. Zhu, Y.-Q. *et al.* Identification of an NDM-5-producing Escherichia coli Sequence Type 167 in a  
439 Neonatal Patient in China. *Sci. Rep.* **6**, 29934 (2016).
- 440 34. Yap, P. S. X. *et al.* Intestinal carriage of multidrug-resistant gram-negative bacteria in preterm-infants  
441 during hospitalization in neonatal intensive care unit (NICU). *Pathog. Glob. Health* **110**, 238–246  
442 (2016).
- 443 35. Soo, P. *et al.* Intestinal carriage of multidrug-resistant gram-negative bacteria in preterm-infants during  
444 hospitalization in neonatal intensive care unit ( NICU ). *Pathog. Glob. Health* **110**, 1–9 (2016).
- 445 36. Naha, S. *et al.* KPC-2-producing Klebsiella pneumoniae ST147 in a neonatal unit: Clonal isolates with  
446 differences in colistin susceptibility attributed to AcrAB-TolC pump. *Int. J. Antimicrob. Agents* **55**,  
447 105903 (2020).
- 448 37. Zhao, W., Chen, G., Ito, R., Kimura, S. & Hu, Z. Identification of a plasmid-borne bla IMP-11 gene in  
449 clinical isolates of Escherichia coli and Klebsiella pneumoniae. 246–251 (2012).  
450 doi:10.1099/jmm.0.035626-0
- 451 38. Ding, Y., Wang, Y., Hsia, Y., Sharland, M. & Heath, P. T. Systematic review of carbapenem-resistant  
452 Enterobacteriaceae causing neonatal sepsis in China. *Ann. Clin. Microbiol. Antimicrob.* **18**, 36 (2019).
- 453 39. Zeng, K.-J., Doi, Y., Patil, S., Huang, X. & Tian, G.-B. Emergence of the Plasmid-Mediated mcr-1  
454 Gene in Colistin-Resistant Enterobacter aerogenes and Enterobacter cloacae. *Antimicrob. Agents  
455 Chemother.* **60**, 3862–3863 (2016).
- 456 40. Zheng, R. *et al.* Outbreak of plasmid-mediated NDM-1-producing Klebsiella pneumoniae ST105 among  
457 neonatal patients in Yunnan, China. *Ann. Clin. Microbiol. Antimicrob.* **15**, 10 (2016).
- 458 41. Yu, J. *et al.* Nosocomial outbreak of KPC-2- and NDM-1-producing Klebsiella pneumoniae in a  
459 neonatal ward: a retrospective study. *BMC Infect. Dis.* **16**, 563 (2016).
- 460 42. Roy, S., Singh, A. K., Viswanathan, R., Nandy, R. K. & Basu, S. Transmission of imipenem resistance  
461 determinants during the course of an outbreak of NDM-1 Escherichia coli in a sick newborn care unit.

- 462 2773–2780 (2011). doi:10.1093/jac/dkr376
- 463 43. Poirel, L. *et al.* Spread of NDM-1-producing Enterobacteriaceae in a neonatal intensive care unit,  
464 Istanbul, Turkey. *Antimicrob Agents Chemother* AAC. 02047-13 (2014).
- 465 44. Jin, Y. *et al.* Outbreak of Multidrug Resistant NDM-1- Producing Klebsiella pneumoniae from a  
466 Neonatal Unit in Shandong Province , China. 1–11 (2015). doi:10.1371/journal.pone.0119571
- 467 45. Li, J. *et al.* Emergence of an NDM-5-producing Escherichia coli sequence type 410 clone in infants in a  
468 children’s hospital in China. *Infect. Drug Resist.* **13**, 703–710 (2020).
- 469 46. Khatri, A. *et al.* Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing  
470 Klebsiella pneumoniae. *Antimicrob. Agents Chemother.* **59**, 4375–4378 (2015).
- 471 47. Macharashvili, N. *et al.* Etiology of neonatal blood stream infections in Tbilisi, Republic of Georgia. *Int.*  
472 *J. Infect. Dis.* **13**, 499–505 (2009).
- 473 48. Mairi, A., Pantel, A., Sotto, A., Lavigne, J.-P. & Touati, A. OXA-48-like carbapenemases producing  
474 Enterobacteriaceae in different niches. *Eur. J. Clin. Microbiol. Infect. Dis.* **37**, 587–604 (2018).
- 475 49. Stoesser, N. *et al.* Genome sequencing of an extended series of NDM-producing Klebsiella pneumoniae  
476 isolates from neonatal infections in a Nepali hospital characterizes the extent of community- versus  
477 hospital-associated transmission in an endemic setting. *Antimicrob. Agents Chemother.* **58**, 7347–7357  
478 (2014).
- 479 50. Saleem, A. F., Qamar, F. N., Shahzad, H., Qadir, M. & Zaidi, A. K. M. Trends in antibiotic  
480 susceptibility and incidence of late-onset Klebsiella pneumoniae neonatal sepsis over a six-year period  
481 in a neonatal intensive care unit in Karachi, Pakistan. *Int. J. Infect. Dis.* **17**, e961–e965 (2013).
- 482 51. Sultan, A. M. & Seliem, W. A. Identifying risk factors for healthcare-associated infections caused by  
483 carbapenem-resistant acinetobacter baumannii in a neonatal intensive care unit. *Sultan Qaboos Univ.*  
484 *Med. J.* **18**, e75–e80 (2018).
- 485 52. Indhar, F., Durrani, M. A., Bux, A. & Sohail, M. care hospital in Karachi Carbapenemases among  
486 Acinetobacter species isolated from NICU of a tertiary care hospital in Karachi. (2017).
- 487 53. Al-lawama, M., Aljbour, H., Tanash, A. & Badran, E. Intravenous Colistin in the treatment of  
488 multidrug-resistant Acinetobacter in neonates. *Ann. Clin. Microbiol. Antimicrob.* **15**, 1–4 (2016).
- 489 54. Kumar, A., Randhawa, V. S., Nirupam, N., Rai, Y. & Saili, A. Risk factors for carbapenem-resistant  
490 Acinetobacter baumannii blood stream infections in a neonatal intensive care unit, Delhi, India. *J. Infect.*  
491 *Dev. Ctries.* **8**, 1049–1054 (2014).
- 492 55. Lee, H. Y. *et al.* Risk factors and molecular epidemiology of Acinetobacter baumannii bacteremia in  
493 neonates. *J. Microbiol. Immunol. Infect.* **51**, 367–376 (2018).
- 494 56. Tekin, R., Dal, T., Pirinccioglu, H. & Oygucu, S. E. A 4-year surveillance of Device-Associated  
495 nosocomial infections in a neonatal intensive care unit. *Pediatr. Neonatol.* **54**, 303–308 (2013).

- 496 57. Li, P. *et al.* ST37 *Klebsiella pneumoniae*: development of carbapenem resistance in vivo during  
497 antimicrobial therapy in neonates. *Future Microbiol.* **12**, 891–904 (2017).
- 498 58. Chen, D. *et al.* Co-outbreak of multidrug resistance and a novel ST3006 *Klebsiella pneumoniae* in a  
499 neonatal intensive care unit: A retrospective study. *Medicine (Baltimore)*. **98**, e14285 (2019).
- 500 59. Arena, F. *et al.* Large oligoclonal outbreak due to *klebsiella pneumoniae* ST14 and ST26 producing the  
501 FOX-7 AmpC  $\beta$ -lactamase in a neonatal intensive care unit. *J. Clin. Microbiol.* **51**, 4067–4072 (2013).
- 502 60. Yu, J. *et al.* Outbreak of nosocomial NDM-1-producing *Klebsiella pneumoniae* ST1419 in a neonatal  
503 unit. *J. Glob. Antimicrob. Resist.* **8**, 135–139 (2017).
- 504 61. Vergadi, E., Bitsori, M., Maraki, S. & Galanakis, E. Community-onset carbapenem-resistant *Klebsiella*  
505 *pneumoniae* urinary tract infections in infancy following NICU hospitalisation. *J. Pediatr. Urol.* **13**,  
506 495.e1-495.e6 (2017).
- 507 62. Liu, Y. *et al.* Acquisition of carbapenem resistance in multiresistant *Klebsiella pneumoniae* isolates of  
508 sequence type 11 at a university hospital in China. *Diagn. Microbiol. Infect. Dis.* **76**, 241–243 (2013).
- 509 63. Kong, Z. *et al.* First reported nosocomial outbreak of NDM-5-producing *Klebsiella pneumoniae* in a  
510 neonatal unit in China. *Infect. Drug Resist.* **12**, 3557–3566 (2019).
- 511 64. Yap, P. S. X., Ahmad Kamar, A., Chong, C. W., Yap, I. K. S. & Teh, C. S. J. Whole genome analysis of  
512 multidrug resistant *Citrobacter freundii* B9-C2 isolated from preterm neonate’s stool in the first week. *J.*  
513 *Glob. Antimicrob. Resist.* **21**, 246–251 (2020).
- 514 65. Rawstron, S. A. *et al.* Perirectal Screening for Carbapenem-Resistant Enterobacteriaceae Obtained From  
515 100 Consecutive Healthy Pregnant Women in Labor at a Brooklyn Hospital: Results and Risk Factors.  
516 *Infect. Control Hosp. Epidemiol.* **39**, 369–371 (2018).
- 517 66. Kothari, C. *et al.* Community acquisition of beta-lactamase producing Enterobacteriaceae in neonatal  
518 gut. *BMC Microbiol.* **13**, 136 (2013).
- 519 67. Turner, P., Neou, L. & Turner, C. High Prevalence of Antimicrobial-resistant Gram-negative  
520 Colonization in Hospitalized Cambodian Infants. **35**, 856–861 (2016).
- 521 68. Zhu, J. *et al.* *Klebsiella pneumoniae*: Development of carbapenem resistance due to acquisition of  
522 blaNDM-1 during antimicrobial therapy in twin infants with pneumonia. *Front. Microbiol.* **6**, 1–5  
523 (2015).
- 524 69. Kopotsa, K., Osei Sekyere, J. & Mbelle, N. M. Plasmid evolution in carbapenemase-producing  
525 Enterobacteriaceae: a review. *Ann. New* **1457**, 61–91 (2019).
- 526 70. Xu, J., Lin, W., Chen, Y. & He, F. Characterization of an imp-4-producing *klebsiella pneumoniae*  
527 st1873 strain recovered from an infant with a bloodstream infection in china. *Infect. Drug Resist.* **13**,  
528 773–779 (2020).
- 529 71. Mammina, C. *et al.* Nosocomial colonization due to imipenem-resistant *Pseudomonas aeruginosa*

- 530 epidemiologically linked to breast milk feeding in a neonatal intensive care unit. **29**, 1486–1492 (2008).
- 531 72. Mazzariol, A. *et al.* A novel VIM-type metallo-beta-lactamase (VIM-14) in a *Pseudomonas aeruginosa*  
532 clinical isolate from a neonatal intensive care unit. *Clin. Microbiol. Infect.* **17**, 722–724 (2011).
- 533 73. Choudhry, S., Ahmad, E., Batool, A. & Raja, N. Use of colistin for the treatment of multi drug resistant  
534 isolates in neonates. **67**, 1157–1160 (2017).

535

536 **Figure 1. Count and isolation rates of Gram-negative bacterial species obtained from**  
537 **pregnant women and infants per country. A-D** shows the count and isolation rates of  
538 carbapenem-resistant Gram-negative bacteria isolated from infants per country, **E** shows the  
539 count and isolation rates of CR-GNB in pregnant women whilst **F** shows the count of  
540 polymyxin-resistant GNB in infants.

541 **Figure 2. Count of Gram-negative bacteria clones infecting or colonizing infants and**  
542 **pregnant women per country. A-B** shows count and prevalence of clones isolated from  
543 infants and **C** shows clones isolated from pregnant women.

544 **Figure 3. Carbapenem and polymyxin resistance rates in Gram-negative bacteria**  
545 **isolated from infants and pregnant women. A and B** show carbapenem resistance rates  
546 from infants and pregnant women respectively, and **C** shows polymyxin resistance rates per  
547 country.

548 **Figure 4. Carbapenemases detected in Gram-negative bacteria per country. A and B**  
549 show carbapenemases detected in bacteria isolated from infants and **C** shows carbapenemases  
550 obtained from pregnant women.

551 **Figure 5. Risk factors associated with carbapenem and polymyxin-resistant Gram-**  
552 **negative bacteria in neonates and pregnant women. A-C** depict risks associated with  
553 carbapenem resistance in neonates, **D** depict risks associated with carbapenem resistance in

554 pregnant women, and **E** depicts risks associated with polymyxin/colistin resistance in  
555 neonates and pregnant women.

556 **Figure 6. Mortality rates associated with carbapenem resistance in infants per country.**

557 **Figure S1. Literature search strategy, inclusion and exclusion criteria employed to**  
558 **arrive at the articles used in this study.**

559 **Figure S2. Isolation rate of Gram-negative bacterial species obtained from infants and**  
560 **pregnant women per country. A** shows the isolation rate of Gram-negative bacteria  
561 obtained from infants per country, **B** shows the isolation rate of Gram-negative bacteria  
562 obtained from pregnant women per country, and **C** shows the isolation rate of polymyxin-  
563 resistant Gram-negative bacteria obtained from infants per country,

564 **Supplemental Table 1.** Data on the epidemiology, risk factors, clinical outcomes, resistance  
565 mechanisms, resistance rates, and prevalence of carbapenem-resistant Gram-negative bacteria  
566 infecting or colonizing infants.

567 **Supplemental Table 2.** Data on the epidemiology, risk factors, clinical outcomes, resistance  
568 mechanisms, resistance rates, and prevalence of carbapenem-resistant Gram-negative bacteria  
569 infecting or colonizing pregnant women.


570 **Supplemental Table 3.** Data on the epidemiology, risk factors, clinical outcomes, resistance  
571 mechanisms, resistance rates, and prevalence of polymyxin-resistant Gram-negative bacteria  
572 infecting or colonizing infants and pregnant women.

573







**A** Carbapenem resistance rate of GNB among infants per country




**B** Carbapenem resistance rate of GNB among pregnant women per country




**C** Polymyxin resistance rate in GNB among infants per country




**A** Carbapenemase detection rate among infants per country








**B** Carbapenemase detection rate among infants per country





**C** Carbapenemase detection rate among pregnant women per country





## Carbapenem resistance-associated infant mortality rates (%) per country





**Figure S1:** Flow diagram showing the results of the literature and database search strategy, inclusion, and exclusion criteria, with reasons.

